Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd's subsidiary, Caplin One Labs Limited, has received a Good Manufacturing Practices (GMP) Compliance Certificate from INVIMA, the regulatory authority in Colombia, for its manufacturing unit. The certificate confirms compliance with GMP requirements for the manufacture of oncology drug products.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd informed about the completion of an unannounced US FDA inspection at its subsidiary Caplin Steriles Limited's manufacturing facility. The inspection was conducted between August 13, 2026, and August 21, 2026, and resulted in 10 observations, all of which are procedural in nature.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has released the transcript of its earnings call for Q1 FY 2026-27, which is available on its website. The company's financial performance for the quarter ended June 30, 2026, is discussed in the call.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has made available the audio recording of its Q1 FY 2026-27 earnings call on its website.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 202.95 crores and net profit for the period at Rs. 120.38 crores. The company has also recommended a final dividend of Rs. 4 per equity share for the financial year ended March 31, 2026. Additionally, the board has approved the re-appointment of Dr. Sridhar Ganesan as Managing Director and the appointment of Mr. D. Muralidharan as Whole-Time Director and Chief Financial Officer.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced the appointment of directors, including the re-appointment of Dr. Sridhar Ganesan as Managing Director and the appointment of Mr. D. Muralidharan as Whole-Time Director and Chief Financial Officer.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of Rs. 120.38 crores. The company has also recommended a final dividend of Rs. 4 per equity share and approved the re-appointment of its Managing Director and the appointment of a new Whole-Time Director.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced the record date for its final dividend as September 18, 2026, ahead of its 35th Annual General Meeting on September 25, 2026.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company has recommended a Final Dividend of Rs.4/- (200%) per equity share of Rs.2/- each for the financial year ended March 31, 2026. The dividend, if approved at the forthcoming Annual General Meeting, shall be paid on or before October 24, 2026. The company has also approved the re-appointment of Dr. Sridhar Ganesan as the Managing Director for a further period of two (2) years, with effect from August 25, 2026, to August 24, 2028, subject to the approval of the Shareholders at the forthcoming Annual General Meeting.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced a post-results conference call invite for the quarter ended June 30, 2026, to discuss the company's financial performance.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve unaudited financial results for the quarter ended June 30, 2026, recommend final dividend for FY 2025-26, convene the 35th Annual General Meeting, and fix the record date for determining shareholder eligibility for the dividend.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd announced the publication of newspaper advertisements on June 22, 2026, regarding the transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF). This is a routine compliance requirement as per the IEPF Authority Rules, 2016. The company is informing eligible shareholders about the process to claim their outstanding dues before the transfer.